TAG:
xifin
Intelligence Briefs September 2026
New Elizabeth Holmes Documentary A new documentary is offering an intimate look at Elizabeth Holmes, the convicted founder of failed blood-testing company Theranos. You Can See Everything, directed by Nathan Fielder and Lance Oppenheim,…
Behind the Cat-and-Mouse Game of Lab Reimbursement
Financial relationships between clinical laboratories and commercial payers have evolved into a high-stakes, technological tug-of-war. For nearly a decade, the clinical laboratory industry has wrestled with the provisions of the Protecting Acce…
October 6, 2025, Intelligence: Late-Breaking Lab News
Bloomberg News has reported that Siemens Healthineers is potentially exploring a sale of its diagnostics division. Several large private equity firms have held early talks with Siemens, including Blackstone, CVC Capital Partners, and KKR & Co., according to Bloomberg. Sourc…
Clinical Labs Battle Complex Claims Denials
CEO SUMMARY: While the number of denials is not going up, the reasons that private payers deny claims are becoming more complex and time-consuming to appeal. After reviewing noteworthy trends among payers, learn a three-level approach to appeals that may lead to greater su…
Don’t Let the Payers Enjoy All the Benefits of Data
PROBABLY SINCE THE ADVENT OF M…
With LDT Rule Vacated, Labs Await FDA Retort
CEO SUMMARY: In a major win for clinical laboratories, a federal judge vacated the FDA’s final rule on LDTs, writing in his decision that the agency overstepped its authority. For now, labs can develop and modify LDTs without FDA oversight, but future action in some form…
November 25, 2024, Intelligence: Late-Breaking Lab News
Disruption is happening in the consumer genetic testing marketplace. In recent weeks, news outlets in the United Kingdom reported that Atlas Biomed, a consumer genetic testing company founded in 2016, had simply “disappeared.” Malwarebytes said Atlas Biomed’s “London offices …
Getting Test Claims Paid & Class Action Lawsuits
When you crack open this issue of The Dark Repor…
Managing Denials and Appeals of Clinical Lab, Path Claims
CEO SUMMARY: Based on a study of denials and appeals involving about 20 million lab test claims, the team at XiFin Inc. presents here their findings. They also provide recommendations on steps labs can take to reduce denials and win a greater proportion of appeals. IN RECENT…
Significant Developments Are Shaping Lab Market
CEO SUMMARY: With 140 speakers and 1,000+ attendees, this year’s Executive War College again provided a comprehensive picture of the specific forces reshaping the U.S. market for lab testing services. Presented here is a smorgasbord of information and innovation shared by different spea…
CURRENT ISSUE
Volume XXXIII, No. 11 – September 2026
In the September 2026 briefing, The Dark Report digs into a CMS proposal to cut payments for CPT code 88305, potentially based on flawed thinking. Other coverage includes the evolving role of mass spectrometry in clinical labs, payer obstacles to blood-based biomarker tests for Alzheimer’s disease, and how young pathologists can get business skill help.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.